Cyclohexane

Cyclohexane

SCHEMBL3364580

C1CCCCC1.C1CCCCC1.CCCC(=O)O

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 2/20 0.81
HDAC3 O15379 1/20 0.81
HDAC1 Q13547 1/20 0.81
HDAC2 Q92769 1/20 0.81
HDAC8 Q9BY41 1/20 0.81
AKR1B1 P15121 1/20 0.52
GPR84 Q9NQS5 7/20 0.50
PPARG P37231 7/20 0.50
PPARD Q03181 7/20 0.50
PPARA Q07869 7/20 0.50
HDAC11 Q96DB2 5/20 0.50
TSHR P16473 4/20 0.50
PTPN1 P18031 3/20 0.50
ALDH1A1 P00352 2/20 0.50
TLR2 O60603 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
FABP4 P15090 2/20 0.50
KMT2A Q03164 2/20 0.50
SLC22A6 Q4U2R8 1/20 0.50
SLC22A8 Q8TCC7 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cyclohexane SCHEMBL16341925 1.00 FFAR3 (0.81) FFAR3HDAC3HDAC1HDAC2HDAC8
Cyclohexane SCHEMBL458810 1.00 FFAR3 (0.81) FFAR3HDAC3HDAC1HDAC2HDAC8
Cyclohexane SCHEMBL7426842 1.00 FFAR3 (0.81) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL11348636 1.00
Cyclohexane SCHEMBL27815810 1.00 FFAR3 (0.81) FFAR3HDAC3HDAC1HDAC2HDAC8
Butyric Acid SCHEMBL3509473 1.00 FFAR3 (0.81) FFAR3HDAC3HDAC1HDAC2HDAC8
Cyclohexane SCHEMBL9778100 0.97 FFAR3 (0.77) FFAR3HDAC3HDAC1HDAC2HDAC8
Cyclohexane SCHEMBL2800628 0.97 FFAR3 (0.77) FFAR3HDAC3HDAC1HDAC2HDAC8
Cyclohexane SCHEMBL1316440 0.97 FFAR3 (0.77) FFAR3HDAC3HDAC1HDAC2HDAC8
Cyclohexane SCHEMBL3247017 0.97 FFAR3 (0.77) FFAR3HDAC3HDAC1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10155751-B2 Pyrazolyl-substituted heteroaryls and their use as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2018-12-18 US disclosed
US-20180148433-A1 New Pyrazolyl-substituted Heteroaryls and their use as Medicaments BOEHRINGER INGELHEIM INT (DE) 2018-05-31 US disclosed
CN-107847921-A Hydrosilylation reaction catalyst 国立大学法人九州大学 2018-03-27 CN disclosed
US-9845314-B2 Pyrazolyl-substituted heteroaryls and their use as medicaments BOEHRNGER INGELHEIM INTERNATIONAL GMBH (DE) 2017-12-19 US disclosed
US-20170073333-A1 New Pyrazolyl-substituted Heteroaryls and their use as Medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2017-03-16 US disclosed
EP-1515965-B1 PHENYLAMINOPYRIMIDINES AND THEIR USE AS RHO-KINASE INHIBITORS BAYER SCHERING PHARMA AG (DE) 2010-10-06 EP disclosed
EP-1476164-B1 QUINOXALINONES AND THEIR USE ESPECIALLY IN THE TREATMENT OF CARDIOVASCULAR DISEASES BAYER HEALTHCARE AG (DE) 2005-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10155751-B2 Pyrazolyl-substituted heteroaryls and their use as medicaments HRH4, HRH3, HRH1 FFAR3 293/4885HDAC3 159/4885HDAC1 246/4885
US-20180148433-A1 New Pyrazolyl-substituted Heteroaryls and their use as Medicaments HRH4, HRH2, HRH3 FFAR3 267/4885HDAC3 139/4885HDAC1 213/4885
US-20170073333-A1 New Pyrazolyl-substituted Heteroaryls and their use as Medicaments HRH4, HRH2, HRH3 FFAR3 267/4885HDAC3 139/4885HDAC1 213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.